	US 12,473,372 B2
	Inhibiting anti-ENPP1 antibodies
Arjun Deb, Los Angeles, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Oct. 26, 2023, as Appl. No. 18/384,176.
Application 18/384,176 is a division of application No. 17/306,544, filed on May 3, 2021, granted, now 11,834,512.
Claims priority of provisional application 63/019,773, filed on May 4, 2020.
Prior Publication US 2024/0294657 A1, Sep. 5, 2024
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 9/10 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01)

CPC C07K 16/2896 (2013.01) [A61P 9/10 (2018.01); C07K 16/40 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)]

13 Claims

1. A method of treating myocardial infarction or improving cardiac wound healing in a subject, comprising administering to the subject an antibody, or antigen-binding fragment thereof, comprising:

i) a heavy chain comprising the CDRH1 of SEQ ID NO: 4, the CDRH2 of SEQ ID NO: 5, and the CDRH3 of SEQ ID NO: 6; and a light chain comprising the CDRL1 of SEQ ID NO: 1, the CDRL2 of SEQ ID NO: 2, and the CDRL3 of SEQ ID NO: 3;

ii) a heavy chain comprising the CDRH1 of SEQ ID NO: 14, the CDRH2 of SEQ ID NO: 15, and the CDRH3 of SEQ ID NO: 16; and a light chain comprising the CDRL1 of SEQ ID NO: 11, the CDRL2 of SEQ ID NO: 12, and the CDRL3 of SEQ ID NO: 13; or

iii) a heavy chain comprising the CDRH1 of SEQ ID NO: 24, the CDRH2 of SEQ ID NO: 25, and the CDRH3 of SEQ ID NO: 26; and a light chain comprising the CDRL1 of SEQ ID NO: 21, the CDRL2 of SEQ ID NO: 22, and the CDRL3 of SEQ ID NO: 23,

wherein the antibody, or antigen-binding fragment thereof, specifically binds to ENPP1.